These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. For research use only.  Legal & Disclaimer

Growth Hormone Secretagogue · GHS-R1a Agonist · GHRP

Ipamorelin
Research Compound

A selective pentapeptide ghrelin receptor agonist developed by Novo Nordisk. Widely referenced in peer-reviewed literature for GHS-R1a binding selectivity and growth hormone axis research. Available in 5mg and 10mg research vials.

5mg & 10mg Vials COA via Krause Analytical HPLC + Mass Spec Sabrina Runbeck, PA-C Finnrick Pulse Verified For Research Use Only

Chemical Identity & Origin

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide belonging to the growth hormone secretagogue (GHS) class, acting as a selective agonist at the growth hormone secretagogue receptor subtype 1a (GHS-R1a), also known as the ghrelin receptor. It was developed by Novo Nordisk in the late 1990s and has since been extensively characterized in the research literature for its receptor pharmacology and its position within the GH/IGF-1 axis.

Peptide Class Growth Hormone Secretagogue (GHS) / GHRP
Receptor Target GHS-R1a (ghrelin receptor)
Structure Pentapeptide: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Residue Count 5 amino acids (includes non-standard residues Aib, D-2-Nal, D-Phe)
Molecular Formula C₃₈H₄₉N₉O₅
Molecular Weight 711.86 g/mol
Origin / Developer Novo Nordisk, late 1990s
CAS Number 170851-70-4
Storage Lyophilized: −20 °C, protected from light and moisture

Structural Note

The inclusion of non-proteinogenic residues — α-aminoisobutyric acid (Aib), D-2-naphthylalanine (D-2-Nal), and D-phenylalanine (D-Phe) — is a deliberate design feature studied in the context of metabolic stability and receptor binding geometry. Published research has examined how these modifications contribute to ipamorelin's resistance to proteolytic degradation relative to endogenous ghrelin.

Published Literature

Research Background

Ipamorelin has been the subject of peer-reviewed investigation across several interconnected research areas within neuroendocrinology and peptide pharmacology. The following areas represent domains in which published literature has examined ipamorelin's properties and interactions.

  • GHS-R1a Receptor Pharmacology. Peer-reviewed research has investigated ipamorelin's binding affinity and selectivity at the ghrelin receptor (GHS-R1a). Studies have characterized its receptor engagement kinetics and compared its binding profile to endogenous ghrelin and to earlier-generation synthetic GHRPs, establishing ipamorelin as a selective reference ligand in GHS-R1a binding research.
  • GHRP Selectivity Studies. A defining characteristic examined in the literature is ipamorelin's restricted receptor activity profile. Published studies have compared ipamorelin against GHRP-2 and GHRP-6, investigating the relative absence of ACTH, cortisol-pathway, and prolactin receptor stimulation. Research has examined the structural basis of this selectivity, including the role of the Aib and D-2-Nal residues.
  • Growth Hormone Axis Research. Published research has examined ipamorelin's effects on pituitary GH release in cell culture and animal models, investigating its position within the growth hormone / IGF-1 signaling cascade. These studies are frequently cited in broader research programs examining pituitary secretagogue pharmacology.
  • Pituitary Signaling Studies. Research has investigated the intracellular signaling mechanisms activated downstream of GHS-R1a engagement, including the roles of cAMP, inositol phosphate pathways, and calcium mobilization in somatotroph cells. Ipamorelin has been used as a tool compound in studies probing these pathways.
  • Combinatorial GH Axis Models. A substantial body of peer-reviewed research has examined ipamorelin in the context of concurrent GHRH receptor activation, studying whether GHS-R1a and GHRH-R co-stimulation produces additive or synergistic responses in GH secretion models. These studies inform the scientific rationale for ipamorelin + CJC-1295 combination research (see below).
  • Metabolic Stability Investigations. Research has examined the in vitro half-life and degradation kinetics of ipamorelin relative to endogenous ghrelin and other synthetic GHRPs, investigating how the non-standard amino acid residues contribute to protease resistance.

PubMed Reference

The full body of peer-reviewed literature on ipamorelin is indexed in the National Library of Medicine. Researchers can access the current publication record at PubMed: ipamorelin.

Dual-Receptor Research Model

Ipamorelin & CJC-1295: The Mechanistic Rationale

Ipamorelin and CJC-1295 are frequently paired in the research literature because they act on distinct, complementary receptors within the growth hormone secretory pathway. Understanding the pharmacological rationale requires distinguishing between their respective targets.

  • Different receptors, same axis. Ipamorelin acts as a GHS-R1a agonist (ghrelin receptor pathway), while CJC-1295 is a GHRH analogue acting at the GHRH receptor (growth hormone-releasing hormone receptor). These are separate receptor populations expressed on somatotroph cells of the anterior pituitary, each coupled to distinct intracellular signaling cascades.
  • Convergent downstream signaling. Published research has examined the hypothesis that GHS-R1a and GHRH-R activation converge on overlapping but mechanistically distinct pathways — with GHS-R1a coupling primarily to phospholipase C and intracellular calcium, and GHRH-R coupling primarily to adenylyl cyclase and cAMP-dependent protein kinase. Research has investigated whether simultaneous engagement of both pathways produces a greater GH secretory response than either pathway alone.
  • A published combinatorial research model. Studies from the early 2000s onward examined the combination of GHRPs and GHRH analogues as a tool for investigating the functional relationship between these two receptor systems. Ipamorelin, due to its selectivity, became a preferred research tool for isolating the GHS-R1a contribution in these combinatorial experiments.

CJC-1295 + Ipamorelin Blend — Available from Sequence Labs

For researchers studying the dual-receptor GH axis model, Sequence Labs carries a pre-blended CJC-1295 + Ipamorelin research preparation (5mg each per vial, $70.99). Independently tested via Krause Analytical with batch-specific COA. For research use only.

View Blend Pricing

Sequence Labs

Research Supply & Quality Standards

Sequence Labs supplies research-grade ipamorelin in lyophilized form, independently tested for identity, purity, and potency at every batch.

≥99%
Verified Purity
HPLC + MS
Dual Verification
3rd Party
Krause Analytical, TX
Batch COA
Publicly Accessible
PA-C
Catalog Review
Finnrick
Pulse Authenticated

Testing Process

Every batch of ipamorelin is sent to Krause Analytical (Austin, TX) — an independent, accredited third-party laboratory — for identity confirmation, purity quantification, and potency verification via high-performance liquid chromatography (HPLC) and mass spectrometry. Batch-specific COAs are published and verifiable through the Finnrick Pulse authentication system. The Sequence Labs catalog is reviewed by a licensed physician assistant (PA-C) for accuracy and scientific integrity.

Available SKUs

Product Size Price Format
Ipamorelin 5 mg $40.99 Lyophilized vial
Ipamorelin 10 mg $71.99 Lyophilized vial
CJC-1295 + Ipamorelin Blend 5 mg ea. $70.99 Lyophilized vial (dual compound)

Laboratory Reference

Reconstitution Reference

The following reference table is provided for qualified laboratory researchers working with lyophilized ipamorelin research preparations. All figures are for calculation reference only. For research use only — not for human use.

Vial Size Solvent Volume Added Resulting Concentration Notes
5 mg 1.0 mL bacteriostatic water 5,000 mcg / mL (5 mg/mL) Standard research preparation
5 mg 2.0 mL bacteriostatic water 2,500 mcg / mL (2.5 mg/mL) Dilute preparation
10 mg 1.0 mL bacteriostatic water 10,000 mcg / mL (10 mg/mL) Concentrated preparation
10 mg 2.0 mL bacteriostatic water 5,000 mcg / mL (5 mg/mL) Standard research preparation

Laboratory Protocol Note

To prepare a research sample: introduce solvent (bacteriostatic water or sterile water for research use) along the inner wall of the vial — do not introduce solvent directly onto the lyophilized cake. Allow the pellet to dissolve by gentle swirling; do not vortex. Store the reconstituted research preparation at 2–8 °C and use within the period specified in the batch COA documentation. For research use only. Not for human use.

Frequently Asked Questions

Common Research Questions

What makes ipamorelin selective compared to other GHRPs?
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that binds selectively to the GHS-R1a receptor with minimal affinity for other receptor subtypes. Published receptor-binding studies have documented the absence of meaningful ACTH, cortisol-pathway, and prolactin receptor activity — effects observed with earlier-generation GHRPs such as GHRP-2 and GHRP-6. The structural modifications — specifically the Aib and D-2-naphthylalanine residues — are studied in the context of conferring this restricted binding profile. For this reason, ipamorelin functions as a standard reference compound in GHRP receptor selectivity research.
Why is ipamorelin often studied alongside CJC-1295?
Ipamorelin acts at the GHS-R1a (ghrelin) receptor, while CJC-1295 acts at the GHRH receptor — two distinct and complementary upstream nodes in pituitary growth hormone secretory signaling. Peer-reviewed research has examined the combined receptor engagement model to investigate whether simultaneous GHS-R1a and GHRH-R activation produces additive or synergistic effects on GH secretory responses. Because ipamorelin's receptor selectivity isolates the GHS-R1a contribution, it is the preferred tool compound for these mechanistic combination studies. Sequence Labs carries a CJC-1295 + Ipamorelin Blend (5mg each, $70.99) for researchers working in this dual-receptor model.
What sizes does Sequence Labs carry?
Sequence Labs stocks ipamorelin in 5mg ($40.99) and 10mg ($71.99) lyophilized research vials. A pre-blended CJC-1295 + Ipamorelin research preparation (5mg each per vial, $70.99) is also available. All sizes are independently tested via Krause Analytical with batch-specific COAs available through the COA Library and Finnrick Pulse verification.
How is Sequence Labs ipamorelin tested?
Every batch is independently tested by Krause Analytical (Austin, TX) using HPLC and mass spectrometry. These two complementary analytical methods confirm compound identity, quantify purity (≥99% standard), and verify potency. Batch-specific Certificates of Analysis (COAs) are publicly accessible via the Sequence Labs COA Library and verifiable through the Finnrick Pulse authentication system. The catalog is additionally reviewed by a licensed PA-C for scientific and regulatory integrity.
Is ipamorelin available for wholesale B2B?
Yes — licensed practitioners, research institutions, compounding pharmacies, and medical spas can access tiered wholesale pricing through the Sequence Labs wholesale portal. Volume-based tiers range from approximately 18% to 32% below retail, with no monthly minimums required. Apply via the Wholesale page or contact Team@SequenceLabs.Health directly for high-volume or institutional inquiry.

Ready to order ipamorelin for your research?

5mg and 10mg research vials in stock. Independently tested via Krause Analytical. COA on every batch. Licensed researchers only.